Canada Markets closed

Claritas Pharmaceuticals, Inc. (KALTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.15900.0000 (0.00%)
At close: 11:08AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.1590
Open0.1256
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1590 - 0.1590
52 Week Range0.0020 - 2.0000
Volume14,866
Avg. Volume20,611
Market Cap5.645M
Beta (5Y Monthly)2.74
PE Ratio (TTM)N/A
EPS (TTM)-0.1520
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Claritas Announces New Registered and Records Office Address, Confirms its Management and Directors and Announces Terms of Initial Tranche of Equity Financing with Alumina Partners

    SAN FRANCISCO, CA and TORONTO, ON, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today announced the Company’s new registered and records office address, confirmed its management and Board of Directors and announced the terms of the initial tranche of equity financing that the company will receive under its equity financing agreement with Alumina Partners (Ontario) Ltd. (“Alumina”) The Company’s new registered an

  • GlobeNewswire

    Claritas Secures $5 Million Equity Financing Facility with Alumina Partners (Ontario) Ltd.

    SAN FRANCISCO, CA and TORONTO, ON, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") is pleased to announce it has entered into an agreement (the “Agreement”) with Alumina Partners (Ontario) Ltd. (“Alumina”), an affiliate of Alumina Partners, LLC, a New York based private equity firm, under which Alumina has agreed to provide, at the option of the Company, up to $5 million in equity financing over a period of 2-years

  • GlobeNewswire

    Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

    SAN FRANCISCO, CA and TORONTO, ON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today outlined the Company’s plans for developing R-107, the Company’s nitric oxide-releasing compound, for multiple clinical indications. Claritas’ Development Strategy for R-107 “Claritas is poised to accelerate development of R-107 for treatment of numerous diseases, disorders and injuries,” stated Robert Farrell, Claritas’ Presid